Registration is now open for the
2013 Lurie Cancer Center
Lynn Sage Breast Cancer Symposium,
Thursday September 26 - Sunday, September 29th
at The Fairmont Chicago.

The optimal management of breast cancer is rapidly evolving. A multidisciplinary team of medical, surgical and radiation oncologists, pathologists, plastic surgeons and genetic counselors are routinely involved in offering treatment recommendations for individual patients with a diagnosis of breast cancer. With the emergence of prevention strategies, women at high risk of developing breast cancer are now evaluated for medical therapies, surgical options and lifestyle changes that may reduce their risk of developing breast cancer. The Lynn Sage Breast Cancer Symposium provides a forum for discussing and presenting laboratory and clinical research concerning the care of patients with breast cancer.

Educational Objectives

At the conclusion of this symposium participants should be able to:

1. Incorporate current guidelines and recent data on local therapies, including advances in surgical and radiation therapy, into the treatment of patients with breast cancer

2. Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision-making for breast cancer when appropriate.

3. Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer.

4. Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient and tumor characteristics.

5. Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients.

6. Discuss high-priority translational research and emerging novel agents that are entering clinical trials for patients with breast cancer.

7. Select eligible patients with breast cancer for promising clinical trials.

8. Integrate molecular markers into sub typing of invasive and non-invasive breast cancer

9. Identify issues of sexuality, intimacy and communication in breast cancer survivors

10. Describe new strategies for management of toxicities related to breast cancer therapy